January 12, 2017
2 min read

Adding nelarabine to hyper-CVAD appears safe, effective in adults with T-ALL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — The addition of nelarabine to a standard hyper-CVAD regimen demonstrated durable overall response and complete remission rates in adults with previously untreated or minimally pretreated T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma, according to study findings presented at the ASH Annual Meeting and Exposition.

Yasmin Abaza, MD, from The University of Texas MD Anderson Cancer Center, and colleagues conducted a single-arm phase 2 study of 67 adults to determine complete remission and overall response rates, as well as to assess the safety of adding nelarabine to standard hyper-CVAD in this patient population.

The researchers administered eight induction cycles of hyper-CVAD during odd courses 1, 3, 5 and 7 and alternated with high-dose methotrexate and cytarabine at even courses. Following induction treatment, patients then were administered monthly vincristine, prednisone, 6- mercaptopurine and methotrexate (POMP) maintenance therapy for 30 months.

Patients received nelarabine (Arranon, GlaxoSmithKline) daily at 650 mg/m2 intravenously for more than 2 hours for 5 days after the eight-cycle induction therapy. The protocol was amended after the first 30 patients to deliver nelarabine after cycles 4 and 5 of induction.

Sixty percent of patients that presented to the study were diagnosed with T-ALL. The median age of the patients was 37 years and more than half (76%) were male.

The researchers eliminated 11 patients after determining they had reached complete response at the time of initial presentation.

Ninety-six percent of patients reached an overall response rate, while 93% achieved complete remission.

Complete remission occurred in 87% of patients with T-ALL and 100% of patients with T-LL.

Forty-four patients were alive at a median follow-up of 35 months and 93% of those patients were in remission.

The probability of CR and overall survival at 3 years was 68% and 65%, respectively. The median OS was 82 months.

The most common neurotoxicity that patients experienced was peripheral neuropathy (69%) and only one patient reported a grade 3 or grade 4 experience.

“Novel strategies, such as the addition of asparaginase and perhaps venetoclax to induction [might] improve outcomes in adult T-cell ALL and T-cell lymphoblastic lymphoma,” Abaza said during the presentation. – by Ryan McDonald

Reference: Abaza Y, et al. Abstract 177. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Disclosure: Abaza reports no relevant financial disclosures. Please see the full study for a list of all other relevant financial disclosures.